Disrupting the brain-computer space to transform lives
It would be wonderful if there was a pill that could treat everyone with epilepsy effectively.
Unfortunately, for 30% of epilepsy sufferers, nothing could be further from the truth. Although there are 36 different drugs available, the incidence of drug-resistant or “refractory” epilepsy has not improved in three decades despite the release of over a dozen new anti-seizure medications.
Recognising the limitations and side effects of drug therapies and existing stimulation systems, Carbon Cybernetics is developing a disruptive electroceutical approach to provide safe and effective therapy.
The incidence of drug-resistant or “refractory” epilepsy has not improved in three decades despite the release of over a dozen new anti-seizure medications.
Transforming Epilepsy Patients Lives – Multi USD Billion Market Opportunity
Carbon Cybernetics’ innovation addresses a multi-billion market opportunity, offering enormous potential to improve the lives of people with epilepsy.
Epilepsy affects around 50 million people globally, with drug-resistant cases constituting 30% of all instances.
Carbon Cybernetics has already built a solid track record of achievement and validation:
As a qualified Early Stage Innovation Company, Australian investors can potentially receive advantageous tax benefits.
We have a clear path to market and welcome interest from investors to join us on this exciting journey.
Proceeding from our successful trials, through clinical trials to market entry, investors will gain from significant value inflection points in the future. We aim to demonstrate first-in-human trials in 2024, with large-scale clinical trials projected for 2026-27, aiming for regulatory approvals in 2028 and US market launch.
With our transformative technology, significant market potential, and a dedicated team, Carbon Cybernetics is driven to succeed by the potential to improve the lives of epilepsy patients and address other important chronic neurological disorders in the future.
Get in touch with us?
We are looking for qualified investors that share our vision. To learn more about participating in our Series A investment round starting in the third quarter of 2023, please contact us or schedule an appointment to speak to our CEO.